TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Status:
RECRUITING
Trial end date:
2028-04-30
Target enrollment:
Participant gender:
Summary
A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI) treatment
Phase:
PHASE2
Details
Lead Sponsor:
Shenzhen TargetRx, Inc.
Collaborators:
Chinese Academy of Medical Sciences First Affiliated Hospital of Zhejiang University Henan Cancer Hospital Nanfang Hospital, Southern Medical University Peking University People's Hospital Ruijin Hospital Shengjing Hospital Shenzhen Second People's Hospital The First Affiliated Hospital of Soochow University Tongji Medical College,Huazhong University of Science &Techonlogy